PSSD Open Evidence Aggregation

Public aggregate results across configured SSRI and serotonin-reuptake rows using generic terms, brand-search terms, and DailyMed public label discovery. Sources: FDA FAERS/AEMS, PubMed, DailyMed, ClinicalTrials.gov, regulator publications, and public EudraVigilance aggregate context.
0 SSRIs 0 sources

Aggregate SSRI Rows

New: see the Synthesis tab for the stratified disproportionality analysis (with positive/negative controls) and the full evidence, methodology, and literature dossier.

Download CSV

Interpretation Guardrails

    Latest Public FAERS/AEMS Quarter

    Reaction Term Set

    Scope & limitations

    Reporting disproportionality only — not incidence, prevalence, risk, or causality. This is a signal-characterisation aid, not medical advice or a manufacturer claim. These are spontaneous-report disproportionality signals reflecting adverse-event reporting during or around treatment; even the core-specific (genital anaesthesia) stratum does not establish that symptoms persisted after discontinuation — PSSD's defining feature — which spontaneous structured data cannot capture. Treat as screening / hypothesis-generating only.

    Stratified Disproportionality

    Latest FAERS/AEMS quarter with locked core-specific and extended-broad reaction strata.

    Rows with fewer than 3 co-reports (n<3) are not evaluable for a signal and are listed, de-emphasized, at the bottom.

    Ranking caution: vortioxetine leads the core-specific stratum on a very small count (n=4, wide CI), and the EMA 2019 PRAC action explicitly excluded vortioxetine and clomipramine from the persistent-sexual-dysfunction labelling — so a high rank here may reflect small-count instability or reporting/notoriety rather than a true molecule difference. See the analysis documents below.

    Analysis Documents

    Loading analysis documents.